AstraZeneca and Daiichi Sankyo shared the pooled analysis behind the refiling of their TROP2 antibody-drug conjugate (ADC) ...

Dizal announces positive pooled data of sunvozertinib in EGFR TKI-resistant NSCLC: Shanghai, China Friday, December 13, 2024, 18:00 Hrs [IST] Dizal, a biopharmaceutical company co ...

Olafertinib is a small molecule commercialized by Fortress Biotech, with a leading Phase II program in Non-Small Cell Lung Cancer.

So, exciting opportunities with EGFR and met ADCs [antibody drug conjugates] as well as EGFR and CD3 T-cell engagers in the ...

Chinese biopharma Hutchmed today announced that the Center for Drug Evaluation of China’s National Medical Products ...

Limited (HCM) announced that the Center for Drug Evaluation of Chinas National Medical Products Administration or ...

The non-small cell lung cancer (NSCLC) drug osimertinib (Tagrisso) was associated with an increased risk of therapy-related ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological disea ...

AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that the FDA has granted a Breakthrough Therapy designation ...

"The breakthrough therapy designation granted by the FDA underscores the significant unmet need for new treatments for patients with previously treated EGFR-mutated non-small cell lung cancer who have ...

Anti-seizure medications, which are also called anticonvulsants or anti-epileptic drugs (AEDs), are medications used to prevent seizures for people who have epilepsy. All AEDs are available only by ...